Clinical outcomes in older adults treated outside clinical studies: highlighting the octogenarian experience
Abstract: With an aging population, multiple myeloma (MM) increasingly affects octogenarians (Octos; age of ≥80 years), yet data on their management and outcomes, particularly if treated outside clinical trials, remain limited. This retrospective study analyzed 652 patients aged ≥70 years, diagnosed...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Blood Advances |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2473952925001491 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850139685906546688 |
|---|---|
| author | Dor Shpitzer Yael C. Cohen Tamir Shragai Ori Grossberger Dana Amsterdam Anat Reiner-Benaim Irit Avivi |
| author_facet | Dor Shpitzer Yael C. Cohen Tamir Shragai Ori Grossberger Dana Amsterdam Anat Reiner-Benaim Irit Avivi |
| author_sort | Dor Shpitzer |
| collection | DOAJ |
| description | Abstract: With an aging population, multiple myeloma (MM) increasingly affects octogenarians (Octos; age of ≥80 years), yet data on their management and outcomes, particularly if treated outside clinical trials, remain limited. This retrospective study analyzed 652 patients aged ≥70 years, diagnosed with active MM between 2014 and 2023, identified in the Maccabi Healthcare Services medical records. Patient characteristics, treatment, time to next treatment (TTNT), overall survival (OS), and factors influencing outcomes, were compared between Octo and older adults (OL) aged 70 to <80 years. Octo patients (median age, 83 years) had more comorbidities and higher Charlson Comorbidity Index (CCI) scores than OL patients (≥6; 53% vs 23%), leading to lower rates of anti-MM therapy administration and reduced triplet/quadruplet regimen use. Over a median follow-up of 25 months, Octo patients had significantly shorter median OS; 25.9 vs 71.3 months, and 33 vs 76.9 months among treated patients only. TTNT was similar (17.8 vs 22.1 months). Multivariate analysis showed that triplet/quadruplet regimen was associated with improved TTNT (hazard ratio [HR], 0.61; P < .001) and OS (HR, 0.63; P < .001) compared with doublets, whereas higher CCI scores and age of ≥80 years predicted worse OS (HR, 1.5; P = .003; and HR, 2.27; P < .001; respectively). Daratumumab-based therapies enhanced TTNT in both age groups (HR, 0.54; P = .017). In conclusion, higher comorbidities in Octo patients adversely affected their management and survival. However, daratumumab positively influenced outcomes, underscoring the need for tailored approaches to optimize treatment in older patients with MM. |
| format | Article |
| id | doaj-art-dbd145bcae87451f90ecffecfc64a245 |
| institution | OA Journals |
| issn | 2473-9529 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Blood Advances |
| spelling | doaj-art-dbd145bcae87451f90ecffecfc64a2452025-08-20T02:30:10ZengElsevierBlood Advances2473-95292025-06-019112677268510.1182/bloodadvances.2025015968Clinical outcomes in older adults treated outside clinical studies: highlighting the octogenarian experienceDor Shpitzer0Yael C. Cohen1Tamir Shragai2Ori Grossberger3Dana Amsterdam4Anat Reiner-Benaim5Irit Avivi6Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Correspondence: Dor Shpitzer, Tel Aviv Sourasky Medical Center, Osishkin 66/2, Tel Aviv 624911, Israel;Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelDepartment of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelDepartment of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelDepartment of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelDepartment of Epidemiology, Biostatistics and Community Health Sciences, School of Public Health, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, IsraelDepartment of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelAbstract: With an aging population, multiple myeloma (MM) increasingly affects octogenarians (Octos; age of ≥80 years), yet data on their management and outcomes, particularly if treated outside clinical trials, remain limited. This retrospective study analyzed 652 patients aged ≥70 years, diagnosed with active MM between 2014 and 2023, identified in the Maccabi Healthcare Services medical records. Patient characteristics, treatment, time to next treatment (TTNT), overall survival (OS), and factors influencing outcomes, were compared between Octo and older adults (OL) aged 70 to <80 years. Octo patients (median age, 83 years) had more comorbidities and higher Charlson Comorbidity Index (CCI) scores than OL patients (≥6; 53% vs 23%), leading to lower rates of anti-MM therapy administration and reduced triplet/quadruplet regimen use. Over a median follow-up of 25 months, Octo patients had significantly shorter median OS; 25.9 vs 71.3 months, and 33 vs 76.9 months among treated patients only. TTNT was similar (17.8 vs 22.1 months). Multivariate analysis showed that triplet/quadruplet regimen was associated with improved TTNT (hazard ratio [HR], 0.61; P < .001) and OS (HR, 0.63; P < .001) compared with doublets, whereas higher CCI scores and age of ≥80 years predicted worse OS (HR, 1.5; P = .003; and HR, 2.27; P < .001; respectively). Daratumumab-based therapies enhanced TTNT in both age groups (HR, 0.54; P = .017). In conclusion, higher comorbidities in Octo patients adversely affected their management and survival. However, daratumumab positively influenced outcomes, underscoring the need for tailored approaches to optimize treatment in older patients with MM.http://www.sciencedirect.com/science/article/pii/S2473952925001491 |
| spellingShingle | Dor Shpitzer Yael C. Cohen Tamir Shragai Ori Grossberger Dana Amsterdam Anat Reiner-Benaim Irit Avivi Clinical outcomes in older adults treated outside clinical studies: highlighting the octogenarian experience Blood Advances |
| title | Clinical outcomes in older adults treated outside clinical studies: highlighting the octogenarian experience |
| title_full | Clinical outcomes in older adults treated outside clinical studies: highlighting the octogenarian experience |
| title_fullStr | Clinical outcomes in older adults treated outside clinical studies: highlighting the octogenarian experience |
| title_full_unstemmed | Clinical outcomes in older adults treated outside clinical studies: highlighting the octogenarian experience |
| title_short | Clinical outcomes in older adults treated outside clinical studies: highlighting the octogenarian experience |
| title_sort | clinical outcomes in older adults treated outside clinical studies highlighting the octogenarian experience |
| url | http://www.sciencedirect.com/science/article/pii/S2473952925001491 |
| work_keys_str_mv | AT dorshpitzer clinicaloutcomesinolderadultstreatedoutsideclinicalstudieshighlightingtheoctogenarianexperience AT yaelccohen clinicaloutcomesinolderadultstreatedoutsideclinicalstudieshighlightingtheoctogenarianexperience AT tamirshragai clinicaloutcomesinolderadultstreatedoutsideclinicalstudieshighlightingtheoctogenarianexperience AT origrossberger clinicaloutcomesinolderadultstreatedoutsideclinicalstudieshighlightingtheoctogenarianexperience AT danaamsterdam clinicaloutcomesinolderadultstreatedoutsideclinicalstudieshighlightingtheoctogenarianexperience AT anatreinerbenaim clinicaloutcomesinolderadultstreatedoutsideclinicalstudieshighlightingtheoctogenarianexperience AT iritavivi clinicaloutcomesinolderadultstreatedoutsideclinicalstudieshighlightingtheoctogenarianexperience |